Investor Overview

NASDAQ: XBIT0.084.25Data provided by Nasdaq.
Minimum 15 minutes delayed.

XBiotech is building on a foundation of remarkable new therapies, innovative approaches to commercialization and a commitment to realizing treatments for unmet medical needs worldwide.

Recent News
05/22/18XBiotech Announces First Patient in Phase 2 Study Evaluating MABp1 in Patients with Atopic DermatitisPrinter Friendly Version
04/16/18XBiotech Announces Upcoming Phase 2 Clinical Studies in DermatologyPrinter Friendly Version
04/02/18XBiotech In-licenses Anti-NY-ESO-1 Antibody Targeting Advanced CancerPrinter Friendly Version

Read more »

Upcoming Events

There are currently no events scheduled.

Read more »